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ABSTRACT
NF-IL6b regulates gene expression and plays
function roles in many tissues. The EGF-regulated
cyclooxygenase-2 (cox-2) expression is mediated
through p38
MAPK signaling pathway and positively
correlates with NF-IL6b expression in A431 cells.
NF-IL6b coordinated with c-Jun on cox-2 trans-
criptional activation by reporter and small interfer-
ing RNA assays. NF-IL6b could directly bind to
CCAAT/enhancer-binding protein (C/EBP) and
cyclic AMP-response element (CRE) sites of the
cox-2 promoter by in vitro-DNA binding assay.
The C/EBP site was important for basal and, to a les-
ser extent, for EGF-regulated cox-2 transcription,
while the CRE site was a more specific response
to EGF inducibility of cox-2 gene. SUMO1 expres-
sion attenuated EGF- and NF-IL6b-induced cox-2
promoter activities. NF-IL6b was found to be
sumoylated by in vivo- and in vitro-sumoylation
assays, and the SUMO1-NF-IL6b (suNF-IL6b) lost
its ability to interact with p300 in in vitro-binding
assay. NF-IL6b was also acetylated by p300, and
acetylation of NF-IL6b enhanced the cox-2 promoter
activity stimulated by NF-IL6b itself. In vivo-DNA
binding assay demonstrated that EGF stimulated
the recruitment of p300 and NF-IL6b to the cox-2
promoter, yet promoted the dissociation of
SUMO1-modificated proteins from the promoter.
These results indicated that NF-IL6b plays a pivotal
role in the regulation of basal and EGF-induced cox-2
transcription.
INTRODUCTION
Prostaglandins play important roles in many biological pro-
cesses, including cell division, immune responses, blood
pressure regulation, ovulation, bone development and
wound healing. The cyclooxygenase (COX, prostaglandin
endoperoxide synthase) is a key enzyme in prostaglandin,
prostacyclin and thromboxane biosynthesis from arachidonic
acid. Two COX isoforms were described (1). COX-1 is con-
stitutively expressed in most tissues and cells in animal spe-
cies. COX-2 is induced by a wide-range of stimulators, such as
IL-1b (2,3), TNF-a (4), IL-18 (2), epidermal growth factor
(EGF) (5) or LPS (6), in many distinct cell types (7–9) and is
regulated mainly at the level of transcription. Human cox-2
promoter region contains a twin arginine translocation A and
multiple regulatory elements, including two putative nuclear
factor-kB (NF-kB) binding sites, one nuclear factor
interleukin-6 (NF-IL6)/CCAAT/enhancer-binding protein
(C/EBP) binding site and one cyclic AMP-response element
(CRE) (10). Recent studies on human cox-2 promoter have
shown that cox-2 transcription is regulated by different tran-
scription factors, including NF-kB (11), NF-IL6/C/EBP (11–
14), C/EBPd (12), CREB (12,13,15) and activation protein
1 complex (AP-1) (5,11), supporting that regulation of cox-2
gene expression could involve complex interactions among
diverse transcription factors. Thus, transcriptional mechanism
of cox-2 induction relies on cell type-speciﬁc as well as com-
bined interactions of several cis-acting regulatory elements,
transcription factors and signal transduction pathways.
The C/EBP family contains three main activating members,
C/EBPa, C/EBPb and C/EBPd, that recognize the same DNA
sequence. These three members have a common structure: an
N-terminal domain bearing the transaction domain, a basic
DNA-binding domain and a C-terminal leucine zipper domain
that allows the homo- or hetero-dimerization of these factors.
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doi:10.1093/nar/gkj422C/EBPd is involved in the ligand-stimulated transcriptional
regulation of cox-2 gene (12). However, the detail molecular
mechanism of human C/EBPd, NF-IL6b, in the regulation of
cox-2 gene transcription is unclear.
Post-translational modiﬁcation of proteins by sumoylation
is an important regulatory mechanism and has been found to
be utilized in many cellular processes (16–18). SUMO modi-
ﬁcation of several transcription factors has been reported,
including the androgen receptor (19), LEF1 (20), c-Myb
(21), TEL (22), Sp3 (23,24), p53 (25), c-Jun (26) and C/
EBPs (26). SUMO conjugation has been shown to regulate
several different protein functions including protein stability,
subcellular localization and transcriptional activation regula-
tion (18,27,28). The consensus sequence, (I/L)KXE, for
sumoylation has been deﬁned (29). The C/EBP family belongs
to the large family of basic leucine zipper (bZIP) transcription
factors. The repression domain I of C/EBPe was demonstrated
to be modiﬁed by SUMO1 (26), and this modiﬁcation was
proposed to be important for the inhibitory function of this
domain. Kim et al. (25) also reported that conserved SUMO
target sequences are present inC/EBPa,C/EBPband C/EBPd,
and that these isoforms can be conjugated to SUMO1 (26).
However, the function of sumoylated C/EBPs is largely
unknown, especially in the case of NF-IL6b.
Coactivatorp300 andCREB-bindingprotein(CBP)serveas
an integrator for gene transcription. Several reports have
suggested involvement of p300 coactivator in cox-2 trans-
criptional regulation (4,5,30). p300 contains histone acetyl-
transferase (HAT) activity that modulates the acetylation of
histones or transcription factors, thus affecting the DNA
binding and transcriptional activation. p300 and CBP have
been shown to participate in C/EBPs-mediated gene transcrip-
tion (31–33). C/EBP family members trigger the phosphoryla-
tion of p300 and consequently increase p300-mediated
transcriptional activation (34).
Several reports have shown C/EBPb and C/EBPd’s invol-
vement in cox-2 gene expression (35,36). However, the
effects of C/EBPs on cox-2 transcription are dependent on
cell type and stage of differentiation. Gain or loss of function
of C/EBPd and C/EBPb regulate cox-2 promoter activity in
various cell types (35,37,38). In our previous study, we found
that induction of c-Jun is involved in EGF-induced cox-2
expression (5). In addition, we found that the level of NF-
IL6b is also elevated by EGF treatment in human epidermoid
carcinoma A431 cells (37). In this study, we extended our
work to investigate the functional role of NF-IL6b in regulat-
ing cox-2 promoter activity in the basal and EGF-induced
transcriptional state, and the effects that sumoylation and acet-
ylation of NF-IL6b play function roles on the promoter. Our
results indicated that NF-IL6b mediates the basal and EGF-
induced cox-2 promoter state, and sumoylation of NF-IL6b
attenuates the activation of cox-2 promoter, while p300 can
acetylate NF-IL6b and participate in the NF-IL6b-enhanced
cox-2 promoter regulation.
MATERIALS AND METHODS
Materials
Human EGF was purchased from Peprotech (Rocky Hill, NJ).
SB203580 was obtained from Calbiochem (San Diego, CA).
Antibodies against COX-2, NF-IL6b, SUMO1 and a-p300-
conjugated agarose were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA). Antibodies against acetyl-lysine
were purchased from Upstate (Charlottesville, VA). Mono-
clonal a-HA antibody was purchased from BM (Boehringer,
Mannheim, Germany). Lipofectamine 2000, Dulbeco’s
modiﬁed Eagle’s medium (DMEM), SuperScriptTM III and
Opti-MEM medium were obtained from Invitrogen (Carlsbad,
CA). All oligonucleotides were synthesized by MDBio Inc.
(Taipei, Taiwan). Fetal bovine serum (FBS) was from
HyClone Laboratories (Logan, UT). Streptavidin–Sepharose
beads were purchased from Amersham Biosciences (Buck,
UK). In vitro transcription/translation kit was purchased
from Promega (Madison, WI). Expression plasmid
pcDNA3/HA was a gift of Dr. Hsin-Fang Yang-Yen (Institute
of Molecular Biology, Academia Sinica, Tapei, Taiwan).
pSliencer
TM 3.0 vector was purchased from Ambion (Austin,
TX). The sumoylation kit was purchased from LAE Biotech-
nology Co. (Taichung, Taiwan). The recombinant p300
protein was purchased from Active Motif (Carlsbad, CA).
The cloning vector, yTA vector, was purchased from Yeastern
Biotech. Co. (Taipei, Taiwan). DNA polymerase kit and BD
Advantage GC
TM PCR kit for PCR-cloning were purchased
from BD Biosciences (Palo Alto, CA). Protein concentration
column, Amicon  Centriprep  Filter Devices, was purchased
from MILLIPORE (Billerica, MA). All other reagents used
were of the highest purity obtainable. The expression vector
TAM-67 encoding the truncated human c-Jun was the
generous gift of Dr M. Birrer (NCI, National Institutes of
Health, Rockville, MD). Small interfering RNA (siRNA)
pool for c-Jun and a non-speciﬁc control siRNA were pur-
chased from Darmacon (Lafayette, CO). pSUPERc-Jun
siRNA was designed and constructed by KRII International
Co. (Taipei, Taiwan).
Plasmid transfection and reporter gene assay
A431 and HeLa cells were maintained in DMEM supplemen-
ted with 10% FBS, 100 mg/ml streptomycin, and 100 U/ml
penicillin. All EGF treatments of A431 cells were in the con-
centration of 50 ng/ml. Cells were transfected with plasmids
by lipofection using Lipofectamine 2000 according to the
manufacturer’s instruction. Cells were replated 24 h before
transfection at an optional density in 3 ml of fresh culture
medium in a 3.5 cm plastic dish. For usage in transfection,
5 ml of Lipofectamine 2000 were incubated with reporter
plasmid and the expression plasmids as indicated in each
experiment, in 2 ml of Opti-MEM medium for 30 min at
room temperature. Total DNA concentration for each experi-
ment was matched with empty vector. Cells were transfected
by changing the medium with 2 ml of Opti-MEM medium
containing the plasmids and Lipofectamine 2000, unless
otherwise stated. Cells were stimulated with EGF when neces-
sary and incubated for 16 h. The luciferase activities in cell
lysates were measured by the luciferase assay system and
determined as described (37). Luciferase activity was normal-
ized per microgram of extract protein.
Small interfering RNAs assay
Two oligonucleotides were synthesized according to the
oligonucleotide design procedure described in the Ambion’s
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CAgCAgAAgTTCAAgAgACTTCTgCTgCATCTCCTggTT-
TTTTggAAA-30 and 50-AgCTTTTCCAAAAAACCAggA-
gATgCAgCAgAAgTCTCTTgAACTTCTgCTgCATCTCCT-
ggCg-30.T h e5 0 ends of the two oligonucleotides were
non-complementary and formed the BamHI and HindIII
restriction site overhangs that facilitated efﬁcient directional
cloning into the pSliencer
TM 3.0 vector. Cell transfection
separately with NF-IL6b siRNA expression vectors (pSi-1)
and pSliencer
TM 3.0 negative control vectors (pSi-C), which
encode a hairpin siRNA whose sequence is not found in the
human genome databases was purchased from Ambion, were
carried out by Lipofectamine 2000 or lipofectin according to
the manufacturer’s instruction. After 24 h recovery in com-
plete medium, RT–PCR or western blotting assay was per-
formed from the transfectants, which had been previously
starved for 6 h and re-stimulated with EGF for 2 h.
DNA affinity precipitation assay
Nuclear extracts from A431 cells with or without EGF treat-
ment were prepared, and DNA afﬁnity precipitation assay was
performed according to the method described previously
(38,39). The 200 mg of lysates extracted from each group
were incubated with 1 mg of biotinylated C/EBP or CRE oli-
gonucleotides in the presence of DNA binding buffer contain-
ing 10 mM Tris–HCl pH 7.5, 50 mM NaCl, 1 mM DTT, 1 mM
EDTA, 10% (v/v) glycerol, 10 mM NaF, 1 mM PMSF, 1 mg
aprotinin/ml, 1 mg leupeptin/ml, 1 mM Na3VO4 and 2 mg
poly(dI–dC). After 1 h of incubation at 4 C, 40 mlo f
streptavidin–Sepharose were added to the reaction mixture
and the incubation was continued for 1 h. The complexes
were then precipitated by centrifugation and washed three
times with DNA binding buffer before they were resolved
by SDS–PAGE and subsequently analysed by immunoblotting
with a-C/EBPd antibodies.
Chromatin immunoprecipitation assay
The chromatin immunoprecipitation (ChIP) assay was carried
out essentially as described by Saccani et al. (40). Brieﬂy,
A431 cells with or without prior stimulation with EGF
were treated with 1% formaldehyde for 15 min. The cross-
linked chromatin was then prepared and sonicated to an
average size of 300–500 bp. The DNA fragments were
immunoprecipitated with antibodies speciﬁc to p300,
SUMO1 and NF-IL6b or control rabbit IgG at 4 C, overnight.
After reversal of cross-linking, the immunoprecipitated
chromatin was ampliﬁed by PCR ampliﬁcation of speciﬁc
regions of the cox-2 genomic locus. The primers were as fol-
lows: COX-2/F-186: 50-CTGGGTTTCCGATTTTCTCA-30,
COX-2/R+49; 50-GAGTTCCTGGACGTGCTCCT-30,C O X -
2/F+800; 50-CTAAGGCAGGTTAAAAAATTGTATTTCC-30
and COX-2/R+1200: 50-TCCCTTGAAGTGGGTAAGTAT-
GTAGTG-30. The ampliﬁed DNA products were resolved by
agarose gel electrophoresis and conﬁrmed by sequencing.
In vitro expression of NF-IL6b proteins
In vitro transcription/translation of NF-IL6b was performed
using 1 mg of pcDNA3-HA/NF-IL6b and a wheat germ
coupled transcription/translation system according to the
instructions provided by the manufacturer. Recombinant
His-tagged NF-IL6b (His/NF-IL6b) and NF-IL6bK120A
(His/NF-IL6bK120A) were generated from the pET-28a (+)
vector. The recombinant plasmids were transformed into
BL21 (DE3) cells. Isopropyl-b-D-thiogalactopyranoside
(IPTG) was used to induce recombinant protein expression
in the transformants. His/NF-IL6b and His/NF-IL6bK120A
were puriﬁed according to the instructions provided by the
manufacturer and dialysed with dialysis buffer (50 mM
HEPES pH7.4, 100 mM NaCl and 1 mM DTT). The dialysed
proteins were concentrated by Amicon  Centriprep  Filter
Devices.
In vitro- and in vivo-SUMO modification assays
In vitro-SUMO modiﬁcation of NF-IL6b was performed using
sumoylation kit. Brieﬂy, assays were performed with 2 mlo f
SAEI and SAEII (7.5 mg/ml), 2 ml of UBC9 (50 mg/ml), 2 mlo f
10· sumoylation reaction buffer (200 mM HEPES, pH 7.5,
50 mM MgCl2 and 20 mM ATP), 2 ml of SUMO1 (50 mg/ml)
and 2 mlo fin vitro-translated HA/NF-IL6b. The reaction
mixture was incubated at 37 C for 30 min and then quenched
with SDS–PAGE sample buffer. The samples were sub-
sequently analysed by SDS–PAGE and immunoblotting
analysis with a-HA antibodies. In vivo-sumoylation assay
was carried out in A431 cells. Cells were transfected with
pcDNA3-HA/NF-IL6b expression vectors in the presence or
absenceofSUMO1-GG. Cell extracts wereprepared insample
buffer (5% SDS, 0.15 M Tris–HCl pH 6.7 and 30% glycerol)
and then diluted 1:3 with RIPA buffer (25 mM Tris–HCl pH
8.2, 50 mM NaCl, 0.5% NP-40, 0.5% deoxycholate and 0.1%
SDS), containing 20 mM N-ethylmaleimide and 1 mM PMSF,
1 mg aprotinin/ml and 1 mg leupeptin/ml for subsequent
immunoprecipitation assay.
In vitro- and in vivo-acetylation assay
Puriﬁed p300 protein (50 ng) and 0.5 mg of the indicated His/
NF-IL6b protein or His/NF-IL6bK120 were incubated in a
reaction mixture containing 50 mM Tris–HCl, pH 8.0, 10%
glycerol, 0.1 mM EDTA, 1 mM DTT and 40 mM acetyl-
coenzyme A for 1 h at 30 C. The reaction mixture was sub-
jected to SDS–PAGE and analysed by western blotting using
anti-a-acetyl-lysine antibodies. In vivo-acetylation assay was
performed by transfecting cells with the pcDNA3-HA/
NF-IL6b expression vectors in the presence or absence of
p300 expression plasmid. Cells were lysed in sample buffer
(50 mM HEPES, pH 7.4, 100 mM NaCl, 1 mM EDTA and 1%
Triton X-100) and then diluted 1:4 with TE buffer (10 mM
Tris–HCl, pH 7.5 and 0.1 mM EDTA), containing 100 mM
sodium butyrate, 1 mM PMSF, 1 mg aprotinin/ml and 1 mgo f
leupeptin/ml for immunoprecipitation assay.
Construction of reporter plasmids and
expression vectors
The cox-2 promoter fragment from  207 to +49 bp ( 207/
+49wt) was obtained by PCR from the pXC918 reporter (5).
The primers used were as follows: COX-2/KpnI-207: 50-
GGGGTACCTGCTCCCAAATTGGGGCAGC-30, COX-2/
HindIII+49: 50-GGAAGCTTGAGTTCCTGGACGTGCTC-
C-30. The PCR fragments were cloned into yTA vector and
veriﬁed by sequencing. A KpnI/HindIII fragment was
subcloned into the multi-cloning sites of the promoter-less
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from  207/+49wt by site-directed mutagenesis of each indi-
vidual region as indicated. Plasmid pGL2-promoter/COX-2/
1XCEBP (pGL2-promoter 1XC/EBP) was derived by insert-
ingonecopyoftheDNAfragmentcontainingtheC/EBPmotif
sequence (50-GGGCTTACGCAATTTTTTTAA-30) into the
SmaI site of the pGL2-promoter vector. NF-IL6b was
generated from human liver cDNA library by PCR using
BD Advantage GC
TM PCR kit and using the following
oligonucleotides: 50-CGGGATCCAGCGCCGCGCTCTTCA-
GCCTG-30 and 50-GGCCTCGAGGCCGCGCGTTACCGGC-
AGTC-30. The ampliﬁed fragment was digested with BamHI
and XhoI and inserted into BamHI- and XhoI-digested
pcDNA3-HA to produce HA-tagged NF-IL6b (HA/NF-
IL6b). The cox-2 promoter plasmids pXC80 and pXC918
have been described previously (5).
RT–PCR
Total RNA was isolated from A431 cells using the TRIzol
RNA extraction kit. Of the isolated RNA 1 mgwas subjected to
reverse transcription with SuperScriptTM III. Speciﬁc
primers for COX-2: 50-CCCACTTCAAGGGATTTT-30 and
50-CCAGACCAAAGACCTCCT-30,and forNF-IL6b:5 0-AG-
CGCAACAACATCGCCGTG-30 and 50-GTCGGGTCTGA-
GGTATGGGTC-30, were used for analyses. The PCR
products were separated by electrophoresis in 1% agarose
gel and visualized with ethidium bromide staining.
p300 pull-down assay
In vitro-translated HA/NF-IL6b (2 ml) were incubated with
puriﬁed p300 protein in a buffer composed of 50 mM
Tris–HCl, pH 8.0, 10% glycerol, 0.1 mM EDTA and 1 mM
DTT. After pulling down by a-p300-conjugated agarose
(p300-AC), the immunoprecipitation pellets were washed
and separated by SDS–PAGE for subsequent detection by
immunoblotting with a-HA antibodies.
RESULTS
p38
MAPK inhibitor attenuates EGF-induced
cox-2 transcription
Recent studies have shown that the known C/EBP family
proteins can modulate cox-2 gene expression through inter-
actions with each other or other transcription factors. Hence
prior to this study, we have veriﬁed the expression of C/EBPs
in the presence of EGF (Figure 1A). According to these
data, the expression pattern of C/EBPa is not affected by
EGF treatment, whereas C/EBPb expression can be greatly
increased by EGF treatment, but only after a 6 h delay.
Otherwise, NF-IL6b pre-existed before EGF treatment
and enhanced by EGF treatment. The induction pattern of
NF-IL6b is similar with c-Jun and COX-2 expression patterns
after EGF treatment.
We previously found that the p38
MAPK signaling pathway
mediates the EGF-induced NF-IL6b transcription in A431
cells (37). To examine the possibility that NF-IL6b regulates
cox-2 gene expression in A431 cells, we ﬁrst studied the cor-
relation between p38
MAPK activation and NF-IL6b/cox-2 gene
transcription. RT–PCR assay was carried out for this study.
The levels of EGF-induced NF-IL6b mRNA and cox-2 mRNA
were attenuated by pretreatment with p38
MAPK inhibitor,
SB203580, in a dose-dependent manner (Figure 1B). The
results suggest a close relationship between EGF-induced
NF-IL6b expression and cox-2 transcription through
p38
MAPK signaling activation.
NF-IL6b plays a functional role in
cox-2 promoter activity
To address and connect whether NF-IL6b would activate the
cox-2 promoter, cells were cotransfected with an NF-IL6b
expression vector and a reporter construct controlled by the
cox-2 promoter. As shown in Figure 2A, overexpression of
NF-IL6b enhanced cox-2 promoter activity in a dose-
dependent manner. The effect could be enhanced by EGF
treatment. The results suggest that NF-IL6b might play a
functional role in the basal and EGF-induced expression
of COX-2.
Figure 1. (A) EGF-induced COX-2 expression and C/EBP protein levels in
A431 cells. Cell lysates were harvested after EGF treatment. Antibodies to
recognize the COX-1, COX-2, c-Jun and C/EBPs protein levels performed by
western blot analysis. (B) SB203580, p38 inhibitor, attenuates EGF-induced
cox-2 transcription in a dose-dependent manner. A431 cells deprived of serum
were pretreated with p38 inhibitor SB203580 for 30 min prior to stimulation
with EGF for 90 min. After stimulation, cells were lysed, and total RNA was
prepared for RT–PCR analysis of NF-IL6b and cox-2 mRNA levels.
220 Nucleic Acids Research, 2006, Vol. 34, No. 1Figure 2. NF-IL6bplaysaroleintranscriptionofcox-2gene.(A)OverexpressionofNF-IL6benhancesthecox-2reporteractivity.A431cellsweretransfectedwith
0.2 mg of reporter vector pXC80 carrying cox-2 promoter ( 80/+49 bp) together with expression vector of NF-IL6b in 1 ml of Opti-MEM medium. After medium
change, cells were treated with or without EGF for 13 h. Cell lysates were then prepared, and luciferase activity was assayed. (B) Silencing of NF-IL6b expression
attenuates EGF-induced cox-2reporteractivity. Cells weretransfected with 1mg ofpXC918 carryingcox-2 promoter ( 918/+49 bp) togetherwith1 mgof pSi-C or
pSi-I. The upper panel shows that the transfection of NF-IL6b expression vectors attenuated the pXC918 reporter activity. The lower panel shows that the
transcriptionalproductsofcox-2andNF-IL6bgeneswhichwereexaminedbyRT–PCRanalysis.ThepSi-CrepresentsthepSilencer
TMnegativecontrolplasmid.The
pSi-IindicatesthespecificNF-IL6bknockdownexpressionvector.(C)ReductionofNF-IL6bexpressiondecreaseCOX-2expression.ThetransfectionofpcDNA3/
HA-NF-IL6b with pSi-C or pSi-I was performed in HeLa cells. Cellular lysates were harvested and analysed by western blotting probed with a-HA, a-COX-2 and
a-b-actin antibodies. b-Actin was used as an internal loading control. (D) Silencing of c-Jun expression attenuates NF-IL6b-induced cox-2 reporter activity. A431
cells were transfected with 0.2 mg of pXC80, together with 0.5 mg of expression vector pSUPERc-Jun siRNA and 0.2 mg of each expression vector of c-Jun and
NF-IL6bin1mlofOpti-MEMmedium.StatisticalsignificancebetweenpSUPERc-JunsiRNA-transfectedanduntransfectedcellswasanalysedbyStudent’st-test.
(E)CooperationofNF-IL6bwithc-Juninpromoteractivationofcox-2gene.A431cellsweretransfectedwith0.2mgofpXC80reportervectortogetherwith0.05mg
ofexpressionvectorofNF/IL6band0.02mgofexpressionvectorofc-Junin1mlofOpti-MEMmedium.Celllysateswerethenprepared,andluciferaseactivitywas
assayed. Statistical significance between c-Jun-transfected and untransfected cells was analysed by Student’s t-test.
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scriptional activation of cox-2 gene, complementary speciﬁc
oligonucleotides aimed to inhibit NF-IL6b gene expression by
RNA interference were designed. Transfection of A431 cells
with the NF-IL6b siRNA expression vector resulted in reduc-
tion of EGF-induced NF-IL6b mRNA and a concomitant
decrease of cox-2 mRNA (Figure 2B, upper panel). Consistent
with the RT–PCR results, cells cotransfected with a luciferase
reporter construct controlled by cox-2 promoter, pXC918 (5),
and an NF-IL6b siRNA expression vectors, pSi-1, expressed
signiﬁcantly less luciferase activity than that cotransfection
with negative control, pSi-C (Figure 2B, lower panel).
Cotransfection of HA/NF-IL6b expression vectors with
pSi-C increased COX-2 expression, but the transfectant
with pSi-1 decreased the COX-2 expression (Figure 2C).
These results suggest that NF-IL6b plays a role in regulating
COX-2 expression. Since c-Jun is involved in EGF-induced
cox-2 transcriptional activation through the CRE binding site
(5,41), we examined whether activation of cox-2 promoter,
which bears a CRE binding site, by NF-IL6b requires the
cooperation with c-Jun. As shown in Figure 2C, cells cotrans-
fected with c-Jun siRNA expression vector reduced NF-IL6b-
induced cox-2 promoter activity, indicating that the activation
of cox-2 promoter by NF-IL6b is, at least in part, dependent on
c-Jun. Furthermore, cotransfection of cells with c-Jun and
NF-IL6bexpressionvectors resulted inasynergisticactivation
of the cox-2 promoter (Figure 2D). Taken together, these
data indicate that NF-IL6b and c-Jun likely co-regulate
EGF-dependent cox-2 expression.
C/EBP and CRE motifs are important for
cox-2 gene activation in A431 cells
To further study whether C/EBP and CRE motifs are involved
in the basal and EGF-induced cox-2 gene regulation, reporter
expression controlled by the wild-type or mutant cox-2 gene
promoter was assessed in transient transfection studies. The
results are summarized in Figure 3B. A point mutation at
the C/EBP motif resulted in 60–70% loss of the basal promoter
activity, but only a 20–30% decrease in EGF-inducible
increase of the promoter activity (compare  207/+49wt
with  207/+49mCEBP). In contrast, a point mutation at
the CRE motif lost  40% of the basal promoter activity
and  45–55% of EGF-inducible activity (compare  207/
+49wt with  207/+49mCRE). The stimulatory effect of
EGF was abolished when both CRE and C/EBP sites were
mutated ( 207/+49mCE/C), suggesting that C/EBP and CRE
motifs are essential for cox-2 promoter activity. These results
demonstrate that CRE motif is more important in EGF
response, while C/EBP site is more important in regulating
the basal cox-2 expression. To evaluate the effect of NF-IL6b
on C/EBP and CRE motifs, the NF-IL6b expression vector
was cotransfected with various mutant cox-2 promoters in
A431 cells. The results are summarized in Figure 3C. The
mutation at C/EBP and CRE sites diminished 75 and 40%,
respectively, of the stimulatory effect of NF-IL6b on the cox-2
promoter (lanes 2 and 3). While the NF-IL6b effect seems to
be more prominent at the C/EBP motif, double mutation at
both sites almost completely abolished the NF-IL6b response
(lane 4). Since NF-IL6b played a functional role in the tran-
scriptional activity of cox-2 promoter, we examined whether
NF-IL6bbindstothe C/EBPor CREmotifs ofcox-2 promoter.
To test the binding activity between CRE and C/EBP motifs,
DNA afﬁnity precipitation assay was performed with nuclear
extracts prepared from control and EGF-treated A431 cells.
As seen in Figure 3D (lanes 5 and 8), EGF apparently
increased the amount of NF-IL6b bound to the C/EBP and
CRE motifs of cox-2 promoter.
Sumoylation plays a negative regulatory role in
cox-2 promoter activation
Base on these results, we have veriﬁed that NF-IL6b play a
functional role in cox-2 transcription. We then tried to elucid-
ate the mechanism in which NF-IL6b modulates the basal and
EGF-induced transcriptional regulation of cox-2 gene. C/
EBPd was reported to be a SUMO1 substrate in vitro and
in vivo, and a K120A mutant of the Gal4-C/EBPd(1–142)
fusion protein lost  60% of its repressive activity, as com-
pared with the wild-type Gal4-C/EBPd(1–142) protein (26).
To investigate whether sumoylation acts on the transcription
factors for the cox-2 promoter, transient reporter assay was
performed. Cotransfection of the SUMO1 expression vector
signiﬁcantly repressed the NF-IL6b-enhanced pXC918
reporter activity (Figure 4A, compare lanes 3 and 4 with
lanes 5 and 6). To speciﬁcally examine whether the C/EBP-
binding complex participated in the SUMO-mediated repress-
ive effect, a heterologous reporter pGL2 promoter-C/EBP was
used, and the NF-IL6b-enhanced pGL2 promoter-C/EBP
reporteractivitycouldbeattenuatedbyexogenouslyexpressed
SUMO1 (compare lanes 9 and 10 with lanes 11 and 12). These
results suggest that sumoylation might suppress cox-2 pro-
moter activity under the EGF-deprived condition, and that
the C/EBP motif might be the site of SUMO-mediated effect.
NF-IL6b is a SUMO substrate
Although the mouse C/EBPb has been shown to be a target for
SUMO1, sumoylation of human C/EBPd (NF-IL6b) and its
biological function have not been elucidated. By sequence
comparison between mouse C/EBPd and NF-IL6b, the
consensus sequence for SUMO attachment, LKREP, in the
regulatory domain motif (RDM) was conserved. To examine
whether NF-IL6b is a SUMO substrate, in vitro-sumoylation
assay was carried out with puriﬁed E1 (SAEI and SAEII), E2
(Ubc9) and in vitro-transcribed/translated HA/NF-IL6b.
SUMO1 or SUMO3 could be covalently conjugated to HA/
NF-IL6b in vitro (Figure 5A, lanes 3 and 4). To map the site of
sumoylation, we ﬁrst examined the sequence and found a
region between amino acid 110 and 151 in HA/NF-IL6b
contained a potential sumoylation site (data not shown).
Thelysine 120inthisregionhasbeen reportedtobeapotential
site of sumoylation (26). A K120A mutation was then gener-
ated by mutagenesis in HA/NF-IL6b to see whether sumoyla-
tionoftheproteinwasaffected.AsshowninFigure5B(lane4),
the K120Amutant proteincouldnotbesumoylated by invitro-
sumoylation assay, suggesting that lysine 120 is the site of
sumoylation. Since post-translational modiﬁcations of tran-
scription factor often affect their DNA binding, the DNA-
binding activity of NF-IL6b and suNF-IL6b was examined
by gel-shift assay using in vitro-translated HA/NF-IL6b
protein and labeled CRE or C/EBP probes. NF-IL6b bound
to DNA as a homodimer (our observation, data not shown).
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motif at the cox-2 promoter (Figure 5C, lane 2). Interestingly,
it also bound to the CRE motif (Figure 5C, lane 5), a result
subsequently conﬁrmed with puriﬁed His/NF-IL6b protein
(data not shown). Using equal amount of the proteins, we
found no appreciable differences between HA/NF-IL6b and
sumoylated HA/NF-IL6b, in term of DNA-binding and
homodimerization activities (Figure 5C, compare lane 2 with
lane 3, or lane 5 with lane 6). We next examined whether the
turnover rates (half-life) of NF-IL6b and NF-IL6bK120A are
Figure 3. C/EBP and CRE motifs play functional role in EGF-induced cox-2 gene activation in A431 cells. (A) Schematic representation of constructs used in this
study.Themutatedsequencesineachindividualconstructareshowninlowercase.(B)TheC/EBPandCREmotifsareimportantforcox-2geneactivation.A431cells
transfectedwith2mgofindicatedreporterscontainingsite-directedmutagenesisofcox-2promoterweretreatedwith(blackcolumn)orwithout(whitecolumn)EGF
for 16 h (right panel). Cell lysates were then prepared, and luciferase activity was assayed. Each group was performed with triplicate assays. In the left panel, three
independent assayswere performed, and the relativeEGF inducibilityto wildand mutantpromoterswascompared.Statisticalanalysiswas performedby Student’s
t-test.(C)BothCREandC/EBPmotifsareimportantoncox-2promoteractivity.A431cells,transfectedwith1mgofindicatedreporterstogetherwithanexpression
vector encoding NF-IL6b or an empty vector, were left in medium without EGF treatment for 16 h. Cell lysates were prepared, and luciferase activity was assayed.
Thegraphshownisarelativeresult.RatiobetweentheluciferaseactivityofeachreportercotransfectedwithNF-IL6bexpressionvectorandthatcotransfectedwith
emptyvectorwascalculated,andthennormalizedbyassigningtherelativeluciferaseratioof 207/+49wtto avalueof100%.(D) NF-IL6b bindstotheC/EBPand
CREelementsinDNAaffinityprecipitationassay.NuclearextractswereharvestedfromcellstreatedwithEGFandincubatedwithbiotin-labeledoligonucleotides.
The precipitated products pulled down by streptavidin–Sepharose were analysed by western blotting with a-C/EBPd antibodies.
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points post-cycloheximide treatment, and exogenously
expressed HA/NF-IL6bwt or HA/NF-IL6bK120A in cell
lysates were analysed by western blotting. We measured the
different time points of remained HA/NF-IL6b proteins and
separately normalize with the ‘0’ time point. As shown in
Figure 5D, the turnover half-life of HA/NF-IL6bwt was
 3.5–4 h, similar to that of HA/NF-IL6bK120A. There was
also no appreciable difference in the patterns of nuclear loc-
alization between the wild-type and K120A mutant NF-IL6b
proteins (data not shown). These results suggest that NF-
IL6bK120A has the same DNA-binding activity, protein
half-life and nuclear localization as NF-IL6bwt. We
then moved on toaddressthe issue ofwhetherNF-IL6bK120A
K120A is involved in the transactivation activity of cox-2
transcription.
The regulatory domain motif of C/EBPs is critical for
inhibitory domain function (26). To test whether the
SUMO-conjugated NF-IL6b is important for silencing cox-2
transcription, we ﬁrst examined whether NF-IL6b is a sumoy-
lated protein in A431 cells. The in vivo-sumoylation assay was
performed by transfecting cells with expression vectors of
SUMO1 active form and HA/NF-IL6b or HA/NF-
IL6bK120A. western blotting analysis indicated that the
suHA/NF-IL6b was detectable in A431 cells. HA/NF-IL6b
was endogenously sumoylated in cells (Figure 6A, compare
lane 1 with lane 3), and the sumoylated HA/NF-IL6b was
increased when cells were cotransfected with SUMO1
(Figure 6A, compare lane 3 with lane 4). However, the no
SUMO-conjugated patterns were seen when HA/NF-
IL6bK120A was cotransfected with the SUMO1-GG expres-
sion vector (Figure 6A, compare lanes 3 and 4 with lanes 5 and
6). Sumoylation of proteins is agent-dependent. For example
PMA can induce Elk-1, but not IkBa, sumoylation in COS7
cells (42). The constitutive sumoylation is also observed
for STAT1 at the lysine703 residue (43). We therefore
investigated whether EGF regulates SUMO1 conjugation to
NF-IL6b in A431 cells. Using immunoprecipitation and
western analysis, we found EGF attenuated the content of
suNF-IL6b in A431 cells (Figure 6B, compare lane 1 with
lane 2, and lane 3 with lane 4). Finally, the transactivation
activity of NF-IL6bwt and NF-IL6bK120A mutant was evalu-
ated in co-transfection studies. The results indicate that the
K120A mutant contributes higher reporter activities than the
wild-type NF-IL6b on the  207/+49wt reporter (Figure 6C,
compare lanes 1 and 2 with lanes 5 and 6) suggesting that an
intact lysine 120 of NF-IL6b is necessary for the repression in
cox-2 transcription.
NF-IL6b is a HAT (p300) substrate
A previous study reportedthatPU.1 could enhance p300 medi-
ated-C/EBPb acetylation (44). Although C/EBPs were repor-
ted to interact with p300 (31,33,45), no evidence to date
suggests that NF-IL6b is an acetylated protein including
C/EBPd. To address this issue and verify that EGF regulates
cox-2 transcription through p300 (41), we investigated
whether acetylated NF-IL6b (acNF-IL6b) is detectable in
A431 cells. Using a-acetyl-lysine antibodies, we were able
to analyse immunoprecipitated products, from the cell lysates
containing endogenous p300. We found that EGF enhanced
the acetylation of HA/NF-IL6b (Figure 7A, compare lanes
3 with 4). Furthermore, exogenously expressed p300-
enhanced NF-IL6b acetylation (Figure 7B, compare lanes
3 and 4 with lanes 5 and 6). To conﬁrm our in vivo data,
an in vitro-acetylation assay was performed using puriﬁed
p300 with His/NF-IL6b or His/NF-IL6bK120A. Despite
removing the acetylation site at lysine 120, p300 is still
able to acetylate NF-IL6bK120A at other unknown site
(Figure 7B, compare lanes 3 with 5). To examine whether
NF-IL6b was involved in an increase in p300 transactivation
activity, we perform a reporter assay by cotransfection of p300
Figure 4. Sumoylation plays a negative regulation role in cox-2 promoter. Cells transfected with 1 mg of pXC918 luciferase reporter vector (A) or C/EBP-
heterologous reporter vector (B) together with 0.5 mg of indicated expression vector were treated with or without EGF for 16 h. Cell lysates were performed, and
luciferase activity was assayed. Each group was performed with triplicate assays.
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expression vectors of NF-IL6b. The knockdown of exogenous
expression of NF-IL6b inhibited p300/NF-IL6b-involved
cox-2 reporter activity (Figure 7C). Additionally, to dissect
whether K120A mutant participated in the p300 transaction
activity, cox-2 reporter assay was carried out by combination
of p300 with NF-IL6b or K120A expression vectors. Exogen-
ous p300 proteins exhibited higher cox-2 promoter/reporter
activity regardless whether wild-type or K120A mutant of
NF-IL6b was used (Figure 7D, compare lanes 1 with 3 and
lanes 2 with 4). These results suggest that NF-IL6b is a HAT
(p300) substrate and the position of lysine120 on NF-IL6b is
not absolutely critical for p300 action.
SUMO1 represses p300-enhanced
cox-2 promoter activity
Our results proposed that NF-IL6b acts as a bifunctional tran-
scription factor on cox-2 gene suppression and activation by
post-translational modiﬁcation. To examine whether post-
translated NF-IL6b could bind to the cox-2 promoter
in vivo, a ChIP assay was performed for NF-IL6b, SUMO1
and p300. EGF treatment increased the level of binding of
NF-IL6b to the cox-2 promoter. (Figure 8A, compare lanes 3
with 4). The binding activity of SUMO1-modiﬁed proteins
was abundant on cox-2 promoter but decreased after EGF
treatment (Figure 8A, compare lanes 5 with 6). Lastly, without
Figure 5. NF-IL6bisatargetforattachmentofSUMO.(A)NF-IL6bisaSUMO1andSUMO3substrateinvitro.Invitro-sumoylationassayusinginvitro-translated
HA/NF-IL6b and SUMO1 or SUMO3 protein were performed as described in Materials and Methods. The reaction mixtures were separated by SDS–PAGE and
blotted with a-HA antibodies. (B) Lysine120 (K120) of NF-IL6b is a SUMO1-conjugated site. In vitro-sumoylation assay was performed as in A. The reaction
mixtures were separated by SDS–PAGE and blotted with a-HA antibodies. (C) suNF-IL6b does not affect DNA-binding activity. Gel-shift assay with
32P-labeled
C/EBP or CRE probes and equal mass of in vitro-translated NF-IL6b (lanes 2 and 6), or suNF-IL6b (lanes 3 and 6) wasperformed.(D) K120A mutanthas the same
protein turnover rate with wild-type NF-IL6b. Cells transfected with 0.5 mg of expression vector of HA/NF-IL6bwt or HA/NF-IL6bK120A were treated with or
without EGF in the presence of 10 mg/ml cycloheximide. Cell lysates were then prepared, and the immunoblotting was performed using a-HA antibodies. The
graph was plotted by normalizing the level of HA/NF-IL6b or HA/NF-IL6bK120A at each time point, and each protein level at time zero point was assigned to a
value of 100%.
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promoter (Figure 8A, compare lanes 7 with 8). The results
indicated that EGF increased the binding of p300 and NF-IL6b
but reduced the binding of SUMO1-modiﬁed proteins on the A
region of cox-2 promoter.
SinceEGFdecreasedsumoylation andincreased acetylation
of NF-IL6b in A431 cells, we then studied whether suNF-IL6b
lost its ability to interact with p300. Using western blotting
assay, we demonstrated that p300 could not bind to the
suNF-IL6b (Figure 8B, compare lanes 3 and 4 with lanes 7
and 8). This result suggested that non-sumoylated or de-
sumoylated NF-IL6b is available for the recruitment of
p300 and support our hypothesis that suNF-IL6b mediates
transcriptional inactivation, while p300 and NF-IL6b/acNF-
IL6b could mediates transcriptional activation of cox-2 gene.
DISCUSSION
A number of recent reports described a role of MAPKs sig-
naling in the induction of cox-2 gene in several cell types (46–
49). In A431 cells, we demonstrated that U0126, a MEK1
inhibitor, and SP600125, a JNK inhibitor, repressed EGF-
induced cox-2 transcription (5). Multiple cell signaling path-
ways including Src  focal adhesion kinase (FAK), PI3-K,
p70S6 kinase, and MAPKs (p38 and ERK1/2) are involved
in type I collagen-induced activation of C/EBP and CREB in
serum-stimulated macrophages (12). Pharmacological inhibi-
tion of PI3-K, ERK1/2 activation, and p38 MAPK activity
suppressed cox-2 induction by EGF in CaSki human cervical
cancer cell line (50). Our previous study also indicated that
PI3-K/p38
MAPK pathways mediate EGF-regulated NF-IL6b
transcriptional activation (37). Thus, p38
MAPK contributes
to the cox-2 transcriptional activation was veriﬁed, and we
also provide a possible linkage of p38
MAPK/NF-IL6b pathway
regulated cox-2 transcription in A431 cells.
CREB and AP-1 (c-Jun/c-Fos) have been reported to bind to
the CRE cis-acting element in human cox-2 promoter (5,50–
53). We previously demonstrated that c-Jun is involved in
EGF-induced cox-2 transcription through transactivation of
CRE binding site in A431 cells (5,41). AP-1 transcription
factor mediates bombesin-stimulated cox-2 expression in
intestinal epithelial cells (46), but has not been linked to
the modulation of endogenous expression in epithelial cancer
cells. In this study, we provided several lines of evidence
suggesting that NF-IL6b is involved in the regulation of
cox-2 by transactivating the CRE site on promoter. The C/
EBPs binding consensus sequence is T (T/G)NNGNAA(T/G).
Several reports (11–14) have shown that C/EBPb or C/EBPd
could bind to the C/EBP motif, CTTACGCAATG, of human
cox-2 promoter using in vitro-binding assay. However, the
CRE motif, ATTTCGTCACATG, is also a putative C/
EBPs-like motif (the underlined sequence). By gel-shift
assay, we found that puriﬁed or in vitro-translated NF-IL6b
could directly bind to the C/EBP and CRE motif on cox-2
promoter (Figure 5C) and EGF treatment enhanced the bind-
ing of NF-IL6b to the CRE site (Figure 3D). The same phe-
nomenon of C/EBPd binding to the C/EBP and CRE sites was
also observed in the LPS- and TPA-regulated cox-2 gene (54).
Moreover, overexpression of NF-IL6b transactivated not only
C/EBP motif but also CRE motif on cox-2 promoter
(Figure 3C) and cotransfection of cells with c-Jun and NF-
IL6b expression vectors resulted in a synergistic activation of
the cox-2 promoter bearing CRE site (Figure 2E). These res-
ults support the notion that NF-IL6b-bound C/EBP motif
coordinates with the CRE motif transactivated by NF-IL6b
and c-Jun in the promoter activation of cox-2 gene upon by
EGF treatment. EGF activated heterologous pGL2 promoter-
C/EBP reporter activity about 4- to 5-folds (Figure 4B), sug-
gesting that C/EBP motif is responsive to EGF stimulation.
Figure 6. EGF attenuates NF-IL6b sumoylation. (A) NF-IL6b sumoylation
invivo.CelllysateswerepreparedfromA431cellstransfectedwith1mgofeach
indicatedexpressionvector,andthewesternblottingwasperformedwitha-HA
antibodies.ArrowsignrepresentsthepositionofsuHA/NF-IL6b (lanes3or4).
(B) EGF attenuates HA/NF-IL6b sumoylation in A431 cells. Cells transfected
with expression vectors as indicated were treated with or without EGF. Cell
lysates were then prepared, and immunoprecipitated with specific SUMO1
antibodies. The immunoprecipitated products were analysed by a-HA
antibodies and quantified with densitometer. The ‘Input’ represents the
lysates containing exogenous HA/NF-IL6b before immunoprecipitation step.
(C) NF-IL6bK120A increased cox-2 reporter activity. Cells transfected with
plasmid 0.5 mgo f 207/+49wt together with 0.1 or 0.5 mg of each expression
vectors as indicated were treated with or without EGF. Cell lysates were then
prepared, and luciferase activity was assayed.
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expression of NF-IL6b was observed using pXC918 ( 918/
+49)(Figure 4A, lane 3),  207/+49wt (JM Wang et al., unpub-
lished data) and C/EBP-heterologous reporters (Figure 4B,
lane 9). However, EGF could not obviously enhance these
cox-2 reporter activities, suggesting that the overexpressed
NF-IL6b may have enough ability to directly recruit the
cofactors and create a more intact transcription initiation
complex, such as CBP or p300 (31), to mimic EGF
stimulation. These results suggested that NF-IL6b plays a
role at the switch control in cox-2 transcriptional
regulation.
Figure 7. NF-IL6b is a HAT(p300) substrate.(A) EGF stimulationincreasesNF-IL6b acetylationin vivo.The lysates, preparedfrom cells transfected with 1 mgo f
each indicated expression vector with or without EGF treatment, were immunoprecipitated with specific anti-acetyl-lysine antibodies. The immunoprecipitation
products were analysed by a-HA antibodies. (B) p300 acetylates NF-IL6b and NF-IL6bK120A in vitro. In vitro-acetylation assay using purified p300 protein and
His/NF-IL6borHis/NF-IL6bwasperformedasdescribedinMaterialsandMethods.(C)SilencingofNF-IL6bexpressionattenuatesp300/NF-IL6b-enhancedcox-2
promoter activity. Cells transfected with 0.5 mg of reporter plasmid  207/+49wt together with 0.5 mg of each expression vector as indicated were left in medium
withoutEGFtreatmentfor16h.Celllysateswereprepared,andluciferaseactivitywasassayed.(D)Overexpressionofp300increasesNF-IL6b-induced 207/+49wt
reporter activity. Cells transfected with 0.5 mg of reporter plasmid  207/+49wt together with 0.5 mg of each expression vector as indicated were left in medium
without EGF treatment for 16 h. Three independent experiments were performed, and the statistic analysis was performed by Student’s t-test.
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SUMO-mediated suppression of the promoter have been
reported (27,28,55). Sumoylation plays a role in cox-2 gene
expression (Figure 4). Several possible regulating proteins
have been proposed for the transcription regulation of cox-2
gene, such as histone H4 (56), C/EBPs (5) and p300 (5,38).
However, nobody has yet examined the transient change
between basal level and ligand-stimulation of cox-2 gene
expression. Our study focuses on a novel NF-IL6b-regulated
pathway, involving post-translational modiﬁcation of the pro-
tein to regulate cox-2 transcription. Recently, Kim et al. (25)
reported the inhibitory function of C/EBPs by Gal4 fusion
protein assay system and showed that lysine 120 was a
potential SUMO-conjugated site on C/EBPd. Therefore, we
demonstrated NF-IL6b is a SUMO1 and HAT substrate and
can regulate the cox-2 transcriptional regulation. We intro-
duced the same point mutation into NF-IL6b and conﬁrmed
that lysine 120 was likely a SUMO-conjugated site (Figure 5B
and 6A). The K120A mutant of NF-IL6b retained the same
DNA binding activity, homodimerization activity, protein
stability and nuclear localization as the wild-type NF-IL6b
(Figure 5C and D). However, comparing with NF-IL6bwt,
it enhanced the transcriptional activation (Figure 6C)
suggesting that the post-translational modiﬁcation might be
involved in the modulation of critical protein–protein inter-
action. Although our reporter assay suggested that suNF-
IL6b plays a repressive function role on cox-2 promoter
(Figure 6C), we did not rule out the possibility that other
Figure 8. NF-IL6bbindstothecox-2genepromoterinvivo.(A)ChIPanalysiswasperformedasdescribedinMaterialsandMethods.Theupperpanelindicatesthe
scheme of 50-flanking region of cox-2 gene, and the location of designed primers for PCR. Chromatin from A431 cells with or without EGF treatment was
immunoprecipitated with specific antibodies as indicated and the cox-2 promoter region was amplified by PCR. (B) Purified p300 proteins cannot interact with
suNF-IL6b. The pull-down assay was performed using the mixtures of purified p300 protein incubated with in vitro-translated HA/NF-IL6b with or without
sumoylationenzymesasdescribedinMaterialsandMethods.The‘C’representsthecontrolproductsofinvitrotranscription/translationreactionwithpCDNA3/HA
vector;the‘Su-C’representstheproductswereperformedbyinvitro-translatedcontrolproductsin invitro-sumoylationreaction.Westernblotsofreactionmixture
(left panel) and a-p300-immunoprecipitated pellet (right panel), using a-HA antibodies, are indicated.
228 Nucleic Acids Research, 2006, Vol. 34, No. 1SUMO-modiﬁed proteins might be involved in the mainten-
ance of the state of repression. Several SUMO-regulated tran-
scription factors could interact with various HDACs resulting
in gene repression. For example, sumoylation of Elk-1 results
in the recruitment of HDAC-2 and hence transcriptional
repression at Elk-1 target genes (4). HDAC1 decreases
LPS-induced cox-2 gene expression had been reported,
although the mechanism of recruitment is still not clear (4).
Our preliminary results from the DNA afﬁnity precipitation
assay demonstrated that suNF-IL6b could increase the inter-
action with some HDACs including HDAC1 (JM Wang et al.,
unpublished data.) These results suggest that suNF-IL6b has
the ability to recruit HDACs to regulate gene expression.
p300 acts as a coactivator for many transcription activators
to modulate basal- and enhancer-regulated transcriptional
activation (57). C/EBPb binding and p300 recruitment are
required for phorbol 12-myristate 13-acetate (PMA)-
induced cox-2 transcription (38). We previously reported
that p300 plays a functional role in EGF-induced cox-2 pro-
moter activity (5). Transcriptional activation by C/EBPa and
C/EBPb coordinated the coactivators, CBP and p300, which
promote transcription by acetylating histones and recruiting
basal transcription factors (58,59). p300/CBP acetylates the
histone tails of nucleosomes, thus favoring chromatin remod-
eling and activation of transcription (60). In this study,
exogenously expressed p300 could increase the NF-IL6b-
mediated cox-2 promoter activity (Figure 7D). We also
demonstrated that p300 could directly acetylate NF-IL6b
in vitro (Figure 7B) and EGF enhances acetylation of
NF-IL6b in vivo (Figure 7A). The most interesting thing is
lysine 120 of NF-IL6b can be a sumoylation or acetylation
site. The same phenomenon occurs in Sp3 (61). The in vivo
studies of something site capable of being both sumoylated
and acetylated are difﬁcult to carry out. Nevertheless, it can
explain why the repression and activation effect of
NF-IL6bK120A is not obvious. In addition, our experiments
in this paper suggest that p300 and NF-IL6b/AcNF-IL6b were
involved in the EGF-induced cox-2 transcription. This cova-
lent modiﬁcation might further enhance the architectural
stability of the whole general basal transcription factors on
cox-2 promoter. By ChIP assays, we showed that EGF
enhanced cox-2 promoter binding activities of both p300
and NF-IL6b. (Figure 8A). The inability of suNF-IL6b to
interact with p300 was also demonstrated by in vitro-binding
assay (Figure 8B). Taken together, these results indicate that
suNF-IL6b and acNF-IL6b are involved, respectively, in the
silencing and activation of cox-2 transcription. The dynamic
pattern of histone H4 acetylation has been demonstrated to
associate with cox-2 transcription by bradykinin and IL-1b
(62). Thus, different acetylation patterns of histones, in con-
junction with acNF-IL6b or other modulators, may result in
conformationalchangesofchromatinandselective association
of transcription factor to the cox-2 promoter. We provided
evidence to support that NF-IL6b is a sumoylated protein
and also acetylated by EGF treatment in A431 cells. It brings
us to deliberate the interplay between the post-translational
modiﬁcation and ligands-induction ofNF-IL6bin downstream
target genes. C/EBP proteins could be modiﬁed by SUMO-1
attachment within their RDM sequences (25). In vitro-
acetylation assay shown NF-IL6b at least have two acetylation
sites (Figure 7B).TheRDM sequences ofC/EBPproteinsexist
in the related region. Moreover, C/EBPb was identiﬁed to be
an acetylated protein (63). The similar phenomenon of acet-
ylation site of C/EBPb occurs nearby to its DNA binding
domain. Align and compare the lysine residues in NF-
IL6b lysine 184, mouse C/EBPd-lysine 184, human C/
EBPb-lysine 264 and mouse C/EBPb-lysine 215, we found
these lysine residues close to DNA binding domain are con-
served. However, the exact acetylation site on NF-IL6b and
whether the reciprocal action of suNF-IL6b and acNF-IL6b is
involved in chromatin remodeling needs to be examined.
In addition to stabilization and de novo synthesis of tran-
scription activators, a gene can also be regulated by post-
translational modiﬁcations of pre-existing transcription fac-
tors. Here, we use the NF-IL6b-regulated cox-2 system to
establish a model that links pre-existing NF-IL6b and its
post-translationally modiﬁed form to regulate cox-2 transcrip-
tion. The present study clearly indicated that NF-IL6b and its
sumoylation and acetylation modiﬁcations play a functional
role in the regulation of cox-2 promoter. NF-IL6b regulated
the basal and EGF-induced cox-2 gene expression (Figure 9).
In resting cells, sumoylation of NF-IL6b attenuated the activa-
tion of cox-2 gene promoter. Upon EGF treatment, the recruit-
ment of p300 and NF-IL6b to the cox-2 gene promoter is
enhanced, while the sumoylated form of NF-IL6b on gene
promoter is attenuated. It suggests that EGF treatment
could result in a decrease in SUMO1-modiﬁed proteins or
suNF-IL6b, an increase of NF-IL6b protein bound to the
cox-2 promoter and the recruitment of p300 and involvement
of NF-IL6b acetylation activate the promoter activity of cox-2
Figure 9. NF-IL6b is a bifunctional protein in cox-2 transcription. In the resting cell stage, suNF-IL6b recruits HDACs to play a repressor role and result in
inactivation of cox-2 transcription. Presence of EGF, p300 could bind to NF-IL6b. Once recruited, p300 can acetylate NF-IL6b, cooperate with NF-IL6b/ c-Jun
complex and result in conformational changes of chromatin to form a more stable transcription initiation complex.
Nucleic Acids Research, 2006, Vol. 34, No. 1 229gene. These results demonstrated a possible interaction
between p300 and the post-translational modiﬁcation of
NF-IL6b in controlling the cox-2 gene expression.
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